Kimura Motohiko, Sasagawa Toru, Tomita Yoshihiko, Katagiri Akiyoshi, Morishita Hideo, Saito Toshihiro, Tanikawa Toshiki, Kawasaki Takashi, Saito Kazuhide, Nishiyama Tsutomu, Kasahara Takashi, Hara Noboru, Takahashi Kota
Department of Urology, Niigata Kobari Hospital.
Hinyokika Kiyo. 2003 Dec;49(12):709-14.
Seventeen patients were given lower dose and intermittent oral administration of estramustine phosphate (6 mg/kg/day) and etoposide (30 mg/m2/day) for 7 days. Then administration was discontinued for 7 days. This administration cycle was repeated. Therapy was continued until evidence of disease progression or unacceptable toxicity occurred. Fifteen of the 17 patients were finally evaluated for PSA response. Overall, the pretreatment PSA levels were lowered at least 50% from baseline in 7 (47%) of the 15 patients. The median survival was 65 weeks. Five of the 17 patients complained of anorexia or nausea during the treatment, but none of them showed over grade 2 anorexia, none requiring transfusion or hospitalization. None of the patients showed edema, deep venous thrombosis, thrombocytopenia, anemia or myocardial infarction. Because of its rare and mild adverse effects, this intermittent administration of oral estramustine and oral etoposide may be a useful and secure regimen for hormone refractory prostate cancer.
17例患者接受较低剂量的磷酸雌莫司汀（6毫克/千克/天）和依托泊苷（30毫克/平方米/天）间歇口服给药，持续7天。然后停药7天。重复这个给药周期。治疗持续进行，直到出现疾病进展的证据或不可接受的毒性反应。17例患者中有15例最终接受了前列腺特异性抗原（PSA）反应评估。总体而言，15例患者中有7例（47%）的治疗前PSA水平较基线至少降低了50%。中位生存期为65周。17例患者中有5例在治疗期间出现厌食或恶心，但均未出现2级以上厌食，无人需要输血或住院治疗。没有患者出现水肿、深静脉血栓形成、血小板减少、贫血或心肌梗死。由于其不良反应罕见且轻微，这种口服磷酸雌莫司汀和口服依托泊苷的间歇给药可能是激素难治性前列腺癌一种有用且安全的治疗方案。
